Clinical Trials Logo

Clinical Trial Summary

THERATEST is looking to collect data from 30 patients actively receiving de-escalation treatments or other standard of care treatments in two UK hospitals. THERATEST is a feasibility study to determine whether patients are willing to be recruited, the impact of de-escalation treatments on patients' cancers and quality of life, whether we should proceed with these treatments in a larger study, and if so how the study should be conducted. A feasibility study prepares the ground for a larger study and improves the chances of the subsequent study producing valuable evidence, and helps to avoid wasting precious resources on larger trials that are unlikely to be informative. We hope that information from THERATEST will bridge the current knowledge gap and allow clinicians to design bigger trials to actively compare the different treatment strategies.


Clinical Trial Description

THERATEST is an observational cohort study of patients receiving SOC treatments (combination chemotherapy or radiotherapy) or de-escalated treatments (primary rRPLND or Carboplatin AUC10) treatments for stage II seminoma. Potential patients will be identified and invited to join the THERATEST study. Patients will be allocated to the following cohorts based on whether the relevant mode of treatment is adopted as an institutional SOC in their respective institution: A. rRPLND cohort: Patients with seminoma who are negative/low for tumour markers and unifocal ipsilateral Stage IIA or <3cm IIB will be assessed for rRPLND. Patients who are eligible for rRPLND will undergo surgery followed by adjuvant treatment or surveillance as determined by their clinical teams based on post-operative histology as per SOC. Patients who are not deemed eligible for or decline rRPLND, will be offered either BEP/EP chemotherapy or radiotherapy with or without neoadjuvant Carboplatin AUC7 and will continue to be followed in the study. B. Carboplatin AUC10 cohort: Patients with stage II seminoma will be offered Carboplatin AUC10. Those deemed ineligible for Carboplatin AUC10 or who decline this treatment option will be offered either BEP/EP chemotherapy or radiotherapy and will continue to be followed in the study. Chemotherapy treatment strategies and adjuvant treatments are left to the shared decision-making between treating clinician and patient and follow institutional SOC. In both cohorts patients will be followed up for 2 years after treatment completion or until death or withdrawal of consent, whichever is the earliest. Beyond the study period, patients will be follow up as per institutional SOC protocols as part of prospective institutional audits. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06309745
Study type Observational
Source Queen Mary University of London
Contact Theratest study coordinator
Phone 020 7882 8478
Email bci-theratest@qmul.ac.uk
Status Recruiting
Phase
Start date January 25, 2024
Completion date December 2027

See also
  Status Clinical Trial Phase
Recruiting NCT06133543 - Robot-assisted ICG-guided Sentinel Node Biopsy in Testicular Cancer N/A
Recruiting NCT05529251 - De-escalation Study for Stage IIa/IIb < 3 cm Seminoma Phase 2
Completed NCT00705094 - Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients N/A
Active, not recruiting NCT03158064 - Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors Phase 2
Recruiting NCT01887340 - Therapeutic Strategy Guided by PET-TDM for Patients With Seminoma Phase 2
Active, not recruiting NCT01593241 - Therapy De-escalation in Seminoma Stage IIA/B Phase 2
Recruiting NCT04876456 - A Phase II Trial of Cabozantinib With Patients With Refractory GCTs Phase 2
Active, not recruiting NCT03937843 - Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma Phase 2
Recruiting NCT04435756 - A Study of miRNA 371 in Patients With Germ Cell Tumors
Active, not recruiting NCT02834013 - Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Phase 2
Recruiting NCT04914026 - MicroRNA as Markers in Testicular Cancer
Not yet recruiting NCT05142982 - Radiotherapy vs Observation for Post Chemotherapy Residual Mass in Advanced Seminoma N/A
Active, not recruiting NCT02375204 - Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors Phase 3
Recruiting NCT06144736 - PRIMETEST II - Clinical Stage II A/B Seminoma Treated With RA-RPLND Phase 2
Recruiting NCT02341989 - Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer Phase 3